Department of Pharmacy and Pharmacology, University of Bath, Bath, UK.
Br J Pharmacol. 2018 Jul;175(14):2869-2880. doi: 10.1111/bph.14060. Epub 2017 Nov 6.
The κ receptor antagonists have potential for treating neuropsychiatric disorders. We have investigated the in vivo pharmacology of a novel buprenorphine analogue, BU10119, for the first time.
To determine the opioid pharmacology of BU10119 (0.3-3 mg·kg , i.p.) in vivo, the warm-water tail-withdrawal assay was applied in adult male CD1 mice. A range of behavioural paradigms was used to investigate the locomotor effects, rewarding properties and antidepressant or anxiolytic potential of BU10119. Additional groups of mice were exposed to a single (1 × 2 h) or repeated restraint stress (3× daily 2 h) to determine the ability of BU10119 to block stress-induced analgesia.
BU10119 alone was without any antinociceptive activity. BU10119 (1 mg·kg ) was able to block U50,488, buprenorphine and morphine-induced antinociception. The κ antagonist effects of BU10119 in the tail-withdrawal assay reversed between 24 and 48 h. BU10119 was without significant locomotor or rewarding effects. BU10119 (1 mg·kg ) significantly reduced the latency to feed in the novelty-induced hypophagia task and reduced immobility time in the forced swim test, compared to saline-treated animals. There were no significant effects of BU10119 in either the elevated plus maze or the light-dark box. Both acute and repeated restraint stress-induced analgesia were blocked by pretreatment with BU10119 (1 mg·kg ). Parallel stress-induced increases in plasma corticosterone were not affected.
BU10119 is a mixed κ/μ receptor antagonist with relatively short-duration κ antagonist activity. Based on these preclinical data, BU10119 has therapeutic potential for the treatment of depression and other stress-induced conditions.
This article is part of a themed section on Emerging Areas of Opioid Pharmacology. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.14/issuetoc.
κ 受体拮抗剂具有治疗神经精神疾病的潜力。我们首次研究了一种新型丁丙诺啡类似物 BU10119 的体内药理学。
为了确定 BU10119(0.3-3mg·kg,i.p.)在体内的阿片类药物药理学,我们在成年雄性 CD1 小鼠中应用了温水尾部退缩试验。使用一系列行为范式来研究 BU10119 的运动效应、奖赏特性以及抗抑郁或抗焦虑潜力。另外一些小鼠组接受单次(1×2 小时)或重复束缚应激(每天 3 次,每次 2 小时),以确定 BU10119 阻断应激诱导性镇痛的能力。
BU10119 本身没有任何镇痛活性。BU10119(1mg·kg)能够阻断 U50,488、丁丙诺啡和吗啡引起的镇痛作用。BU10119 在尾部退缩试验中的κ 拮抗剂作用在 24 至 48 小时之间逆转。BU10119 没有显著的运动或奖赏作用。与盐水处理的动物相比,BU10119(1mg·kg)显著减少了新奇性诱导的摄食量任务中的进食潜伏期,并减少了强迫游泳试验中的不动时间。BU10119 在高架十字迷宫或明暗箱中均无显著作用。急性和重复束缚应激诱导的镇痛均被 BU10119(1mg·kg)预处理阻断。平行的应激诱导的血浆皮质酮增加没有受到影响。
BU10119 是一种混合的 κ/μ 受体拮抗剂,具有相对较短持续时间的 κ 拮抗剂活性。基于这些临床前数据,BU10119 具有治疗抑郁症和其他应激诱导疾病的潜力。
本文是关于阿片类药物药理学新兴领域的专题的一部分。要查看该部分中的其他文章,请访问 http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.14/issuetoc。